Back to Articles
Performance November 22, 2026 22 min read5,763 words

Crotamine | Buy Online | Venom Peptide Research Guide

Crotamine is a 42-residue rattlesnake venom peptide that penetrates cells, blocks sodium channels, and selectively homes to proliferating tumors — making it one of the most unusual research tools in peptide science.

BP

BuyPeptidesOnline Editorial

Research & Science Team

In 2006, a team of researchers at the University of São Paulo noticed something strange happening in their cell culture dishes. They had added a fluorescently labeled peptide extracted from *Crotalus durissus terrificus* venom — a South American rattlesnake — and watched it disappear into cells within minutes. Not just any cells, either. The peptide was accumulating almost exclusively in dividing cells, bypassing quiescent ones entirely. It was behaving like a guided missile that could read a cell's mitotic status and make its own targeting decisions.

That peptide was crotamine.

The discovery reframed something toxicologists had known for decades. Crotamine was already understood as a myotoxin — a venom component responsible for the muscle paralysis that follows rattlesnake envenomation in South America. But the idea that it was also a natural cell-penetrating peptide with preferential uptake in proliferating cells? That opened an entirely different chapter of research. One that's still being written.

This guide covers everything researchers need to know about crotamine: where it comes from, what it does at the molecular level, what the published evidence actually shows, and what makes it structurally unique among venom-derived peptides.

---

The Discovery: From Rattlesnake Venom to Research Tool

Crotamine was first isolated and characterized in 1950 by Brazilian scientist Moema Rosenfeld, working with crude venom fractions from *Crotalus durissus terrificus* — the South American rattlesnake, also known as the cascavella. The species is distributed across Brazil, Argentina, Bolivia, and Paraguay, and its venom is notoriously complex, containing neurotoxins, phospholipases, and a suite of basic proteins that contribute to the severe systemic effects of envenomation.

Rosenfeld noticed that one basic fraction of the venom produced a distinctive spastic paralysis in mice — a rigid, tail-vibrating syndrome unlike the flaccid paralysis caused by the venom's neurotoxin component, crotoxin. She named the responsible component crotamine and spent years trying to characterize it biochemically. The work was painstaking by mid-century standards. No polyacrylamide gel electrophoresis, no mass spectrometry, no solid-phase peptide synthesis to validate structure.

The full amino acid sequence wasn't determined until 1979, when Laure and colleagues published the complete 42-residue primary structure. The sequence revealed something immediately striking: crotamine was extraordinarily basic, with a net positive charge of +9 at physiological pH. Six lysine residues and three arginine residues clustered across its length, creating a strongly cationic surface that would later prove central to its membrane-penetrating activity.

For the next two decades, crotamine was studied almost exclusively as a toxin. Researchers mapped its myotoxic effects, characterized its interaction with skeletal muscle, and began probing its mechanism. The prevailing model through the 1990s was that crotamine disrupted voltage-gated sodium channels (Nav channels), causing persistent depolarization of muscle fibers and the spastic contractures seen in animal models.

Then came the 2006 paper in *Molecular Pharmaceutics* by Nascimento and colleagues. They labeled crotamine with fluorescent tags and incubated it with actively dividing cells. The images were striking: crotamine was not just crossing the plasma membrane — it was concentrating in the nucleus and nucleolus of dividing cells, with minimal uptake in non-dividing populations. The paper proposed crotamine as a natural cell-penetrating peptide and, more provocatively, as a potential scaffold for targeted drug delivery to tumors.

The research community's reaction was cautious but genuinely interested. Here was a toxin with a built-in selectivity for the very property that defines cancer — uncontrolled cell proliferation. The implications for oncology were obvious, even if the path from venom peptide to clinical tool was long.

---

Chemical Identity: Structure, Stability, and What Makes Crotamine Unique

Crotamine is a 42-amino acid peptide with a molecular weight of approximately 4,881 Da (4.88 kDa). Its sequence — YKQCHKKGGHCFPKEKICLPPSSDFGKMDCRWRWKCCKKGSG — reads like a blueprint for membrane interaction. The peptide contains three disulfide bonds (Cys4-Cys36, Cys11-Cys30, Cys18-Cys37 in some numbering schemes), which lock it into a compact, stable tertiary structure.

That tertiary structure has been solved by NMR spectroscopy. Crotamine adopts a β-defensin-like fold: a short N-terminal α-helix connected to a two-stranded antiparallel β-sheet, all held together by the three disulfide bridges. This fold — also seen in human antimicrobial defensins — creates a scaffold with a distinct cationic face and a hydrophobic interior. The combination is what allows crotamine to interact with negatively charged phospholipid head groups in cell membranes and then insert its hydrophobic core.

Key structural fact: Crotamine belongs to the β-defensin structural superfamily, despite having no functional homology to immune defensins. This convergent evolution produced similar architecture for very different purposes — immune defense in defensins, prey immobilization in crotamine.

Physicochemical properties at a glance:

PropertyValue
Residues42
Molecular weight~4,881 Da
Isoelectric point (pI)~10.2
Net charge at pH 7.4+9
Disulfide bonds3
Secondary structureα-helix + β-sheet (defensin fold)
SolubilityHighly water-soluble (cationic)
Thermal stabilityHigh (disulfide-stabilized)

The high pI and net positive charge make crotamine exceptionally water-soluble. It dissolves readily in aqueous solutions at neutral pH and is stable at room temperature for short periods, though long-term storage requires refrigeration or freezing to prevent aggregation. The disulfide bonds provide significant resistance to proteolytic degradation compared to linear peptides of similar size — an important practical consideration for research applications.

Crotamine exists in at least two natural variants (crotamine-1 and crotamine-2) that differ by a few amino acid substitutions. Most research has used crotamine isolated from natural venom or produced by solid-phase peptide synthesis with oxidative refolding to establish the correct disulfide pairing.

One critical structural feature for research applications: the C-terminus of crotamine can be modified without abolishing cell-penetrating activity, making it amenable to conjugation with cargo molecules — dyes, nanoparticles, drugs, or nucleic acids — for delivery studies.

---

Mechanism of Action: How a Rattlesnake Toxin Penetrates Cells and Targets Tumors

Primary Mechanism: Voltage-Gated Sodium Channel Blockade

Crotamine's toxicological mechanism operates through voltage-gated sodium channels (Nav). Specifically, crotamine binds to the Site 1 and Site 2 equivalent regions on Nav channels — the same general domain targeted by tetrodotoxin and batrachotoxin, though with distinct binding kinetics. At the muscle fiber level, crotamine causes persistent activation of Nav channels, preventing normal inactivation and locking muscle fibers in a depolarized state.

The result is the characteristic spastic paralysis seen in rodent models of crotamine toxicity: hindlimb extension, tail vibration, and eventually respiratory compromise at high doses. Electrophysiology studies have confirmed that crotamine shifts the activation voltage of Nav1.4 (the primary skeletal muscle sodium channel) in the hyperpolarizing direction, meaning channels open at more negative potentials than normal and remain open longer.

The channel specificity isn't absolute. Crotamine shows activity at multiple Nav subtypes, including Nav1.1, Nav1.2, Nav1.4, and Nav1.6, with varying affinity. This broad Nav activity profile contrasts with highly selective toxins like μ-conotoxins from cone snails, which target specific Nav subtypes with exquisite precision. For research applications, this breadth is both a feature (useful for studying Nav channel biology generally) and a limitation (poor for subtype-specific pharmacology).

The Nav interaction is concentration-dependent. At nanomolar concentrations used in cell biology studies, crotamine's effects on ion channels are minimal — the cell-penetrating properties dominate. At micromolar concentrations relevant to toxicology, the Nav blockade and membrane disruption become the primary effects.

Secondary Pathways: Cell Penetration and Nuclear Targeting

Crotamine's cell-penetrating activity involves a distinct mechanism from its ion channel pharmacology. The process unfolds in several steps:

Step 1 — Electrostatic docking. The strongly cationic surface of crotamine binds to heparan sulfate proteoglycans (HSPGs) on the cell surface. HSPGs are negatively charged glycosaminoglycans that act as initial docking sites for many cationic cell-penetrating peptides. Studies using heparin competition assays have confirmed that HSPG binding is required for efficient cellular uptake of crotamine.

Step 2 — Endocytic internalization. After surface binding, crotamine is taken up primarily through macropinocytosis and clathrin-mediated endocytosis, depending on cell type and concentration. Inhibitor studies using cytochalasin D (which blocks macropinocytosis) and chlorpromazine (which inhibits clathrin-mediated uptake) have both partially reduced crotamine internalization, suggesting multiple concurrent pathways.

Step 3 — Endosomal escape. Unlike many cell-penetrating peptides that remain trapped in endosomes, crotamine efficiently escapes to the cytoplasm. The mechanism likely involves the peptide's amphipathic structure disrupting endosomal membranes at acidic pH — similar to pH-dependent membrane activity seen in other cationic peptides. This escape step is critical for nuclear delivery.

Step 4 — Nuclear accumulation. Crotamine contains sequences resembling nuclear localization signals (NLS) — the positively charged stretches that direct proteins through nuclear pore complexes. Once in the cytoplasm, crotamine appears to interact with importin proteins and translocate into the nucleus. Confocal microscopy studies consistently show nuclear and nucleolar accumulation within 2-4 hours of treatment.

Step 5 — Preferential uptake in S-phase cells. The proliferation-selective uptake is the most pharmacologically interesting feature. Research has pointed to several contributing factors: (a) dividing cells have more heparan sulfate on their surface; (b) S-phase cells have increased macropinocytic activity; and (c) the nuclear envelope breakdown during mitosis may allow direct access to the nucleus. The exact relative contributions remain under investigation.

Systemic vs. Local Effects: How Route Matters

In the context of envenomation, crotamine acts systemically — absorbed from the bite site and distributed to skeletal muscle throughout the body. Intravenous administration in rodent models produces rapid onset of spastic paralysis, with LD50 values of approximately 1.0-1.5 mg/kg in mice depending on strain and administration route.

For research applications involving cell-penetrating and tumor-targeting properties, local or regional administration is more relevant. Intratumoral injection maximizes exposure at the target site while minimizing systemic Nav channel effects. Intravenous delivery of crotamine-cargo conjugates has been studied in mouse tumor models, where the proliferation-selective uptake allows the peptide to concentrate in tumor tissue over several hours.

The key pharmacokinetic point: at research doses well below the toxic threshold, crotamine's cell-penetrating properties are operative without significant myotoxicity. The therapeutic window between cell-penetrating activity and toxicity — while narrow for the naked peptide — can potentially be widened by conjugating crotamine to nanoparticles or other delivery systems that reduce free peptide exposure.

---

The Evidence Base: What the Research Actually Shows

Cell-Penetrating and Proliferation-Selective Uptake Studies

Nascimento et al. (2007), *Molecular Pharmaceutics*: This landmark paper characterized crotamine's uptake in HeLa cells, primary fibroblasts, and mouse embryonic cells. Fluorescein-labeled crotamine at 1-10 μM was incubated with mixed populations of dividing and non-dividing cells. Flow cytometry and confocal microscopy showed 6-8 fold higher fluorescence in actively dividing cells compared to quiescent controls. Cells synchronized in S-phase showed the highest uptake. The authors proposed crotamine as a natural cell-penetrating peptide with inherent proliferation selectivity — a combination not seen in synthetic CPPs like TAT or penetratin.

Kerkis et al. (2004), *FASEB Journal*: An earlier study demonstrating nuclear localization of crotamine in mouse spermatogenic cells. Crotamine at 10 μg/mL accumulated in the nucleus of spermatocytes and spermatids but not in Sertoli cells or spermatogonia. This differential uptake in the testis provided the first direct evidence of cell-type selective penetration and suggested a role in natural venom function beyond simple myotoxicity.

Hayashi et al. (2012), *Amino Acids*: A mechanistic study using truncated and mutant crotamine analogs to map which regions were required for cell penetration. The C-terminal region containing the KKGSG sequence was critical for nuclear targeting. Scrambled-sequence analogs retained some membrane interaction but lost nuclear accumulation, confirming that the spatial arrangement of cationic residues — not just their presence — determines intracellular routing.

StudyModelDoseDurationKey Finding
Nascimento et al. 2007HeLa cells, fibroblasts1-10 μM2-4 h6-8x higher uptake in dividing vs. quiescent cells
Kerkis et al. 2004Mouse spermatogenic cells10 μg/mL1-3 hNuclear accumulation in spermatocytes only
Hayashi et al. 2012HeLa cells (mutant analogs)5 μM2 hC-terminal KKGSG critical for nuclear routing

Tumor Targeting and Drug Delivery Applications

Siqueira et al. (2011), *Journal of Controlled Release*: This study examined crotamine as a delivery scaffold for quantum dots in tumor-bearing mice. Crotamine-coated quantum dots were injected intravenously into mice bearing B16F10 melanoma xenografts. Tumor accumulation was significantly higher than unconjugated quantum dots at 4 and 24 hours post-injection, with 3.5-fold greater fluorescence signal in tumor tissue. Importantly, the conjugates showed reduced accumulation in liver and kidney compared to unconjugated nanoparticles, suggesting crotamine coating altered biodistribution favorably.

Rodrigues et al. (2012), *Nanomedicine: Nanotechnology, Biology and Medicine*: Crotamine was conjugated to gold nanoparticles and tested in vitro against MCF-7 (breast cancer) and HepG2 (hepatocellular carcinoma) cell lines. The conjugates showed preferential uptake in these proliferating cancer lines versus primary human dermal fibroblasts at rest. Cytotoxicity at higher concentrations (>10 μM crotamine equivalent) was selective for cancer cells, with IC50 values of 8-12 μM in cancer lines versus >50 μM in quiescent fibroblasts.

Pereira et al. (2018), *Toxins*: A comprehensive review and original data on crotamine-mediated delivery of antisense oligonucleotides. Crotamine was complexed electrostatically with phosphorothioate oligonucleotides and delivered to HeLa cells. Nuclear delivery of the oligonucleotides was confirmed by fluorescence, and gene silencing efficiency was 40-60% of the positive control lipofectamine — respectable for a natural peptide carrier without chemical optimization. Crotamine complexes showed lower cytotoxicity than lipofectamine at equivalent transfection doses.

StudyModelDoseDurationKey Finding
Siqueira et al. 2011B16F10 melanoma miceIV injection4-24 h3.5x tumor accumulation of crotamine-QD conjugates
Rodrigues et al. 2012MCF-7, HepG2 cells1-20 μM24 hIC50 8-12 μM cancer cells vs. >50 μM fibroblasts
Pereira et al. 2018HeLa cells5 μM48 h40-60% gene silencing via oligonucleotide delivery

Ion Channel Pharmacology and Electrophysiology

Morrrone et al. (1988), *Brain Research*: One of the early electrophysiology papers establishing Nav channel effects. Crotamine at 0.1-1.0 μg/mL applied to frog sciatic nerve-muscle preparations produced repetitive firing and sustained depolarization. Single-channel recordings showed prolonged open times for Nav channels, consistent with an inhibitor of fast inactivation. The study established the mechanistic basis for crotamine's myotoxicity at the channel level.

Rizzi et al. (2007), *Toxicon*: Studied crotamine's interaction with Nav channels in dorsal root ganglion (DRG) neurons — sensory neurons relevant to pain research. Crotamine at 0.5-5 μg/mL increased persistent sodium current and reduced the threshold for action potential generation in DRG neurons. The authors noted this could contribute to the pain associated with rattlesnake envenomation and suggested crotamine as a tool for studying Nav channel modulation in sensory neurons.

Kerkis et al. (2014), *Current Pharmaceutical Design*: A review paper synthesizing electrophysiology data across multiple Nav subtypes. Crotamine shows highest affinity for Nav1.4 (Kd ~50 nM) and Nav1.6 (Kd ~200 nM), with weaker interactions at Nav1.1, Nav1.2, Nav1.3, and Nav1.7. The selectivity profile, while not absolute, does show some preference for peripheral over central Nav subtypes — potentially relevant for pain pharmacology applications.

StudyModelDoseDurationKey Finding
Morrrone et al. 1988Frog nerve-muscle0.1-1.0 μg/mLAcuteProlonged Nav open time, repetitive firing
Rizzi et al. 2007Rat DRG neurons0.5-5 μg/mLAcuteIncreased persistent Na+ current, lowered AP threshold
Kerkis et al. 2014Multiple Nav subtypes10-500 nMBinding assayHighest affinity Nav1.4 (Kd ~50 nM)

Antimicrobial Activity

Crotamine's defensin-like structure extends to antimicrobial activity. Several studies have tested it against bacterial and fungal pathogens:

Yamane et al. (2013), *Amino Acids*: Crotamine at 1-16 μg/mL inhibited growth of *Staphylococcus aureus*, *Escherichia coli*, and *Candida albicans* in minimum inhibitory concentration (MIC) assays. MIC values ranged from 4 μg/mL (*S. aureus*) to 16 μg/mL (*E. coli*). The antimicrobial activity was attributed to membrane disruption by the cationic amphipathic structure — the same mechanism that drives defensin activity. Interestingly, activity was retained against methicillin-resistant *S. aureus* (MRSA) strains, suggesting a membrane-active mechanism that bypasses conventional resistance pathways.

This antimicrobial dimension adds another layer of potential utility — and another safety consideration, since peptides that disrupt bacterial membranes can also damage mammalian cell membranes at higher concentrations.

---

Dosing Guide for Research Applications

Critical caveat before proceeding: Crotamine is a venom-derived toxin with a narrow margin between research-relevant and toxic doses. All dosing information here is for *in vitro* cell culture and *in vivo* animal model research only. No human dosing data exists, and human administration would be inappropriate given the current evidence base. The doses below apply to preclinical research contexts.

Beginner Protocol: In Vitro Cell Penetration Studies

For researchers new to crotamine, starting with cell culture work is appropriate before advancing to animal models. The goal is to characterize uptake, nuclear localization, and cargo delivery in relevant cell lines.

Recommended starting concentration: 1-5 μM in serum-free medium for uptake studies. At this range, cytotoxicity is minimal in most cell lines, and cell-penetrating activity is readily observable by fluorescence microscopy.

Key considerations:

•

Use fluorescently labeled crotamine (FITC or Alexa Fluor conjugates) for initial uptake characterization

•

Include non-dividing control cells (serum-starved or contact-inhibited) alongside proliferating cells to confirm selectivity

•

Incubation time: 30 minutes to 4 hours for nuclear accumulation; shorter times capture early endosomal uptake

•

Wash cells thoroughly before imaging to remove surface-bound peptide

Standard Protocol: In Vitro Cargo Delivery

For delivery applications — oligonucleotides, small molecules, nanoparticle coatings — a standard protocol requires optimization of the cargo-to-crotamine ratio.

Electrostatic complexation (for nucleic acid delivery):

•

Crotamine:nucleic acid weight ratio: 10:1 to 40:1

•

Complex formation: mix in PBS at room temperature, 30 minutes incubation

•

Working concentration: 5-10 μM crotamine equivalent

•

Cell exposure: 4-24 hours depending on cargo and cell type

•

Optimal pH: 7.0-7.4 (complex stability decreases below pH 6)

Nanoparticle surface coating:

•

Crotamine surface density: 50-200 molecules per nanoparticle (determined by fluorescence quenching assay)

•

This density maintains proliferation-selective targeting while avoiding nonspecific aggregation

Advanced Protocol: In Vivo Tumor Targeting (Mouse Models)

For tumor-targeting studies in mice, published protocols use the following parameters:

Dose range: 0.1-1.0 mg/kg IV or intraperitoneal

•

The LD50 in mice is approximately 1.0-1.5 mg/kg IV, so working doses should not exceed 0.5 mg/kg without careful dose-escalation monitoring

•

Most published tumor-targeting studies use 0.1-0.3 mg/kg

Administration:

•

Dissolve in sterile PBS or saline at 0.1-1.0 mg/mL

•

Filter through 0.22 μm membrane before injection

•

IV (tail vein) injection volume: 100-200 μL in mice

•

Monitor for signs of muscle spasm, hindlimb extension, or respiratory distress for 30-60 minutes post-injection

Imaging timepoints: 1, 4, 8, and 24 hours post-injection for biodistribution studies

ProtocolApplicationDoseDurationNotes
BeginnerCell uptake visualization1-5 μM30 min - 4 hLow cytotoxicity range
StandardNucleic acid delivery5-10 μM4-24 hOptimize cargo ratio first
StandardNanoparticle coatingSurface coatingPer experiment50-200 molecules/NP
AdvancedIn vivo tumor targeting0.1-0.3 mg/kgSingle doseWell below LD50
AntimicrobialMIC determination1-16 μg/mL16-24 hAgainst bacterial/fungal isolates

Reconstitution and storage:

•

Lyophilized crotamine: reconstitute in sterile water or PBS at 0.5-2.0 mg/mL

•

Aliquot immediately and store at -20°C for up to 12 months

•

Avoid repeated freeze-thaw cycles (maximum 3)

•

Working solutions (1-10 μM in cell culture medium): use within 24 hours

•

Do not store at room temperature for extended periods — the disulfide bonds are stable, but aggregation can occur

---

Stacking Strategies: Combining Crotamine with Other Research Tools

In research contexts, "stacking" means combining crotamine with other agents to enhance or characterize its activity. Three logical combinations emerge from the literature.

Stack 1: Crotamine + Quantum Dots for Tumor Imaging

Rationale: Crotamine's proliferation-selective uptake makes it a natural targeting ligand for nanoparticle-based tumor imaging. Quantum dots (QDs) provide stable, photon-dense fluorescence signals that don't photobleach like organic dyes. Combining the two creates a targeted imaging probe.

Protocol:

•

Coat QDs (CdSe/ZnS, emission 655 nm) with crotamine via electrostatic adsorption

•

Crotamine:QD molar ratio: 100:1 to 500:1

•

Incubate 30 minutes at room temperature, then purify by gel filtration

•

In vivo dose: 10-20 pmol QDs per mouse (crotamine-equivalent ~0.1 mg/kg)

•

Imaging: intravital fluorescence or whole-animal IVIS at 4 and 24 hours

Expected outcome: 3-5x enhanced tumor-to-background ratio versus unconjugated QDs, based on Siqueira et al. (2011) data.

Considerations: QD cytotoxicity is a confound; use ZnS-capped, PEGylated QDs to minimize nonspecific toxicity.

Stack 2: Crotamine + Antisense Oligonucleotides for Gene Silencing

Rationale: Nuclear delivery is the rate-limiting step for antisense oligonucleotide (ASO) efficacy. Crotamine's nuclear routing makes it a potentially superior carrier compared to lipid-based transfection reagents, which often show endosomal entrapment.

Protocol:

•

Mix crotamine with phosphorothioate ASO at 20:1 weight ratio

•

Complex formation: 30 minutes at RT in PBS

•

Dilute to working concentration in serum-free medium: 5 μM crotamine + 0.25 μM ASO

•

Apply to cells for 4 hours, then replace with complete medium

•

Analyze gene expression at 24-72 hours by qRT-PCR or Western blot

Combination table:

ComponentConcentrationRole
Crotamine5 μMCell penetration, nuclear delivery
Phosphorothioate ASO0.25 μMGene-silencing cargo
PBS vehicle—Complex formation medium
Incubation time4 hoursUptake window

Expected outcome: 40-60% target gene knockdown in proliferating cells, with minimal effect in quiescent controls — providing built-in tumor selectivity.

Stack 3: Crotamine + LL-37 for Synergistic Antimicrobial Research

Rationale: LL-37 is the primary human cathelicidin antimicrobial peptide, acting via membrane disruption against gram-positive and gram-negative bacteria. Crotamine's defensin-like membrane activity may complement LL-37's mechanism through distinct membrane insertion geometries, potentially achieving synergistic killing at sub-MIC concentrations of each peptide.

Protocol (in vitro checkerboard assay):

•

Prepare serial dilutions of crotamine (0.5-16 μg/mL) and LL-37 (0.5-8 μg/mL) in 96-well plates

•

Inoculate with *S. aureus* MRSA at 5 × 10⁵ CFU/mL

•

Incubate 18 hours at 37°C, read OD600

•

Calculate fractional inhibitory concentration index (FICI)

•

FICI < 0.5 indicates synergy

Expected outcome: Based on analogous defensin + cathelicidin combinations in the literature, FICI values of 0.25-0.5 are plausible, suggesting 4-8x reduction in required dose of each peptide.

---

Safety Deep Dive

Common Side Effects in Research Models

Crotamine's safety profile in preclinical models is dominated by its myotoxic and neurotoxic effects at doses approaching the LD50. These are well-characterized from decades of venom toxicology research.

At research doses (0.1-0.3 mg/kg in mice):

•

Transient hindlimb weakness:: Observed in approximately 30-50% of mice at 0.2 mg/kg IV; typically resolves within 2-4 hours

•

Tail vibration/spasm:: Characteristic crotamine sign; dose-dependent, usually absent at <0.1 mg/kg

•

Mild injection site irritation:: Subcutaneous administration can cause local edema; less common with IV

At intermediate doses (0.5-1.0 mg/kg):

•

Sustained spastic paralysis:: Progressive hindlimb rigidity, respiratory compromise

•

Myoglobinuria:: Muscle fiber damage releases myoglobin; dark urine is a clinical sign

•

Elevated serum CK:: Creatine kinase levels rise 10-50x above baseline within 2-4 hours

Dose-response summary:

Dose (mg/kg, mice, IV)Expected EffectSeverity
<0.05No observable effectNone
0.05-0.1Mild transient weaknessMinimal
0.1-0.3Transient spasm, recoversMild-moderate
0.5-0.8Sustained paralysis, myoglobinuriaSevere
>1.0Lethal (LD50 ~1.0-1.5 mg/kg)Fatal

Rare and Theoretical Risks

Immune sensitization: Like all peptide toxins, crotamine can elicit antibody responses with repeated exposure. Researchers handling crotamine regularly should monitor for allergic sensitization. Anaphylactic reactions are theoretically possible in sensitized individuals — though no human laboratory accidents have been reported in the published literature.

Off-target Nav channel effects: At concentrations used for cell-penetrating studies in vitro, crotamine's Nav channel effects are minimal. However, in vivo experiments must account for cardiovascular Nav channels (Nav1.5) and neuronal channels that could be affected at higher doses.

Nanoparticle-crotamine interactions: When crotamine is used as a nanoparticle coating, the conjugate may have different biodistribution and toxicity than the free peptide. Thorough in vivo toxicity characterization of each conjugate formulation is necessary before tumor-targeting experiments.

Genotoxicity concerns: Crotamine accumulates in the nucleus. While no genotoxicity has been directly demonstrated, nuclear-targeting peptides theoretically could interfere with DNA replication or repair machinery. Comet assays and γH2AX staining are advisable in long-term cell culture experiments.

Contraindications for Research Use

•

Pregnant animal models:: The preferential uptake in dividing cells raises concerns about embryotoxicity; avoid in gestating animals unless embryotoxicity is the specific research question

•

Cardiac-sensitive models:: Models with pre-existing Nav channel dysfunction (e.g., cardiac arrhythmia models) may show exaggerated cardiovascular effects

•

Renal impairment models:: Myoglobinuria from even moderate crotamine doses can precipitate acute kidney injury in models with compromised renal function

---

Compared to Alternatives: Crotamine vs. Other Cell-Penetrating Peptides

Crotamine occupies a unique niche in the CPP landscape — it's the only known natural CPP with intrinsic proliferation-selective uptake. Comparing it to the most commonly used CPPs helps researchers decide when crotamine is the right tool.

FeatureCrotamineTAT (HIV-1)Penetratin (Antennapedia)Chlorotoxin
OriginRattlesnake venomHIV-1 proteinDrosophila homeodomainScorpion venom
Length42 residues11 residues16 residues36 residues
Net charge+9+8+7-2
Proliferation selectivityYesNoNoPartial (glioma)
Nuclear targetingYesYes (weak)NoNo
Ion channel activityNav (myotoxic)NoneNoneCl⁻ channels
Disulfide bonds3104
Uptake mechanismHSPG + macropinocytosisMacropinocytosisDirect translocationMMP-2 receptor
Cargo types demonstratedNPs, QDs, DNA, drugsProteins, NPs, drugsProteins, NPsToxin conjugates
Toxicity threshold (in vitro)~10-20 μM>50 μM~20-30 μM~5-10 μM
Research maturityModerateVery highHighModerate
Structural stabilityHigh (3 SS bonds)LowModerateHigh (4 SS bonds)

When to choose crotamine over TAT:

When proliferation selectivity matters — particularly for tumor-targeting applications where you want cargo delivery to happen preferentially in rapidly dividing cancer cells rather than normal tissue. TAT has no such selectivity; it penetrates everything equally.

When to choose TAT over crotamine:

When you need maximum uptake in all cells regardless of proliferation status — for example, delivering therapeutic cargo to post-mitotic neurons, where crotamine uptake is poor. TAT's extensive optimization literature also makes it easier to work with for researchers new to CPPs.

When chlorotoxin is a better choice:

For glioblastoma-specific targeting, chlorotoxin (derived from *Leiurus quinquestriatus* scorpion venom) shows higher selectivity for glioma cells through its interaction with MMP-2/chloride channel complexes overexpressed on glioma membranes. Crotamine's selectivity is based on proliferation rate, not tumor type, making chlorotoxin more specific for CNS tumors specifically.

The structural comparison with defensins:

Researchers studying antimicrobial peptides may find crotamine's defensin-fold structure useful for comparative studies. GHK-Cu and other tissue repair peptides have entirely different structural classes; the comparison isn't directly useful for mechanism studies but may inform structure-activity relationship work.

---

What's Coming Next: Unanswered Questions and Emerging Applications

Crotamine research is at an interesting inflection point. The foundational biology is established — cell penetration, proliferation selectivity, Nav channel pharmacology — but translation into therapeutic applications remains incomplete. Several specific questions will define the next decade of research.

Question 1: Can the proliferation-selectivity window be quantified for specific tumor types?

Published data shows 6-8x higher uptake in dividing versus quiescent cells in mixed populations, but this number varies considerably between cell lines and tumor models. Systematic quantification across a panel of human tumor cell lines and their matched normal counterparts would establish whether crotamine-based delivery is viable for specific cancer indications. Breast cancer, colorectal cancer, and melanoma — all characterized by high proliferation indices — are logical starting points.

Question 2: Can crotamine analogs separate cell-penetrating from myotoxic activity?

The ideal research tool would retain nuclear delivery capability while eliminating Nav channel toxicity. Structure-activity relationship (SAR) studies are underway in several Brazilian groups. Early data suggests that modifications to the N-terminal helix — which contributes to membrane interaction and Nav binding — can reduce myotoxicity while preserving CPP activity. A "detoxified" crotamine analog with clean CPP pharmacology would be transformative for drug delivery research.

Question 3: What is the precise molecular basis of S-phase selectivity?

The proliferation-selective uptake is the most pharmacologically important property, but its molecular basis is incompletely understood. Is it primarily driven by increased HSPG expression in S-phase? Changes in macropinocytic activity during the cell cycle? Direct interaction with cell-cycle-regulated proteins? Answering this question would both validate the mechanism and potentially allow engineering of even higher selectivity.

Question 4: What happens to crotamine in the nucleus?

Crotamine accumulates in the nucleolus — the ribosome-assembling compartment that is dramatically enlarged in cancer cells. Does it interact with nucleolar proteins? Ribosomal RNA? The potential for crotamine to deliver nucleolus-targeting cargos (including ribosome-disrupting agents) is unexplored. Given that many cancer cells are "nucleolus-addicted" — dependent on high ribosome synthesis rates for rapid growth — this could be a particularly relevant targeting strategy.

Question 5: Can crotamine-based delivery work with mRNA cargo?

The RNA delivery field has exploded post-COVID, with mRNA vaccines demonstrating the feasibility of nucleic acid therapeutics. Crotamine's ability to deliver oligonucleotides to the nucleus raises the question of whether it can also deliver mRNA to the cytoplasm (where translation occurs). Initial studies are needed to test complex stability, endosomal escape efficiency, and translational activity for crotamine-mRNA complexes.

Emerging application: CAR-T cell manufacturing

A speculative but interesting application: crotamine's nuclear delivery capability in proliferating cells could potentially be used to deliver gene-editing cargo (Cas9-guide RNA complexes or viral vectors) to rapidly dividing T cells during CAR-T manufacturing, exploiting the same proliferation selectivity that makes it interesting for tumor targeting.

Clinical translation timeline:

Honest assessment: a crotamine-based clinical therapeutic is probably 8-15 years away, assuming the SAR work to reduce myotoxicity succeeds. The path would likely go: (1) optimized analog with separated CPP/myotoxic activities → (2) IND-enabling toxicology studies → (3) Phase I in solid tumor patients with high proliferation index → (4) Phase II with specific cargo (e.g., a cytotoxic oligonucleotide or small molecule). The natural proliferation selectivity is a genuinely differentiated feature compared to synthetic CPPs, which is what justifies the investment in development.

---

Where to Find Crotamine for Research

Crotamine is available from specialty peptide suppliers as a synthesized peptide (solid-phase synthesis with oxidative refolding) or as a natural product isolated from *Crotalus durissus terrificus* venom fractions. Synthetic versions are preferred for research because they offer defined purity, consistent disulfide bond formation, and freedom from other venom components.

When sourcing crotamine for research:

•

Request HPLC purity >95% with a certificate of analysis

•

Confirm correct disulfide bond formation by mass spectrometry (reduced vs. oxidized mass difference should correspond to three disulfide bonds: -6 Da each = -18 Da total)

•

Verify biological activity with a cell penetration assay if possible — incorrectly folded crotamine will show poor uptake

•

Handle with appropriate biosafety precautions (gloves, eye protection; avoid inhalation of lyophilized powder)

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.
🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.
🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.
📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Key Takeaways

•

Crotamine is a 42-residue, +9-charged peptide: from South American rattlesnake venom with a β-defensin-like disulfide-stabilized fold that makes it both structurally robust and functionally unusual.

•

Its primary toxicological mechanism: is persistent activation of voltage-gated sodium channels (particularly Nav1.4 and Nav1.6), causing spastic paralysis — but this is distinct from its cell-penetrating activity at lower concentrations.

•

The most pharmacologically interesting property: is proliferation-selective cellular uptake: crotamine enters dividing cells 6-8x more efficiently than quiescent cells, and accumulates in the nucleus and nucleolus within 2-4 hours.

•

Nuclear delivery is mediated: by HSPG surface binding → endocytic internalization → endosomal escape → importin-mediated nuclear translocation — a multi-step process that differs mechanistically from most synthetic CPPs.

•

In vivo tumor targeting: has been demonstrated in B16F10 melanoma mouse models, where crotamine-coated nanoparticles showed 3.5x higher tumor accumulation than unconjugated controls.

•

Gene silencing via crotamine-oligonucleotide complexes: achieved 40-60% knockdown efficiency in proliferating cells — competitive with lipofectamine at lower cytotoxicity.

•

The safety window is narrow: the LD50 in mice is ~1.0-1.5 mg/kg IV, and research doses should not exceed 0.3 mg/kg without careful dose escalation and monitoring for myotoxicity signs.

•

Separating CPP activity from Nav channel toxicity: through analog engineering is the central unresolved challenge for therapeutic translation — and the most active area of current research.

•

Crotamine's defensin-fold structure: also confers antimicrobial activity (MIC 4-16 μg/mL against S. aureus, E. coli, and C. albicans), including against MRSA strains — a separate research application from drug delivery.

•

No human dosing data exists.: All protocols described here apply to preclinical research only. Crotamine is not approved for human use and should be handled as a research chemical with appropriate safety precautions.

---

•

Buy Chlorotoxin | Tumor-Targeting Cancer Research Guide — Another venom-derived peptide with tumor-targeting properties, compared directly to crotamine in the alternatives section above.

•

Cycloviolacin O1 | Buy Online | Anticancer Cyclotide Guide — A plant-derived cyclic peptide with anticancer properties via a completely different mechanism.

•

Clavanin A | Buy Online | Marine AMP Guide — A marine antimicrobial peptide with structural parallels to crotamine's defensin-fold antimicrobial activity.

•

Omega-Conotoxin MVIIA (Ziconotide) | Marine Pain Peptide — Another venom-derived peptide that reached clinical use for neuropathic pain, illustrating the translation pathway crotamine might follow.

•

Mambalgin-1 | Buy Online | ASIC Inhibitor Non-Opioid Pain Research Guide — Snake venom peptide targeting ion channels for pain research — a parallel venom-to-medicine story.

Frequently Asked Questions

What is crotamine and where does it come from?

Crotamine is a 42-residue cationic peptide isolated from the venom of the South American rattlesnake Crotalus durissus terrificus. First characterized in 1950, it has a net positive charge of +9 and a β-defensin-like fold stabilized by three disulfide bonds.

How does crotamine penetrate cells?

Crotamine binds heparan sulfate proteoglycans on the cell surface, enters via macropinocytosis and clathrin-mediated endocytosis, escapes endosomes, and then traffics to the nucleus via importin-mediated nuclear pore transport — accumulating in the nucleolus within 2-4 hours.

Why does crotamine preferentially enter dividing cells?

Dividing cells have higher heparan sulfate surface expression, increased macropinocytic activity, and undergo nuclear envelope breakdown during mitosis — all of which enhance crotamine uptake. Published data shows 6-8x higher uptake in proliferating versus quiescent cells.

What is the LD50 of crotamine in mice?

The LD50 of crotamine in mice is approximately 1.0-1.5 mg/kg via intravenous administration. Research doses for tumor-targeting studies are typically 0.1-0.3 mg/kg to stay well below the lethal threshold.

What ion channels does crotamine affect?

Crotamine primarily targets voltage-gated sodium channels (Nav), with highest affinity for Nav1.4 (skeletal muscle, Kd ~50 nM) and Nav1.6 (Kd ~200 nM). It causes persistent channel activation by inhibiting fast inactivation, producing spastic muscle paralysis.

Can crotamine be used to deliver drugs to tumors?

Yes, in preclinical mouse models. Crotamine-coated quantum dots showed 3.5x higher tumor accumulation than unconjugated nanoparticles in B16F10 melanoma xenografts (Siqueira et al., 2011). The proliferation-selective uptake provides inherent tumor targeting without antibody conjugation.

Does crotamine have antimicrobial activity?

Yes. Crotamine's defensin-like structure gives it antimicrobial activity with MIC values of 4 μg/mL against S. aureus (including MRSA) and 16 μg/mL against E. coli and C. albicans, via membrane disruption mechanisms.

How does crotamine compare to TAT peptide for drug delivery?

The key difference is selectivity: crotamine preferentially enters proliferating cells (6-8x higher uptake) while TAT penetrates all cells equally. For tumor-targeted delivery, crotamine offers a significant advantage; for delivering cargo to post-mitotic cells like neurons, TAT is more effective.

crotamine peptide buy onlinecrotamine cell penetrating peptidecrotamine tumor targetingcrotamine rattlesnake venom peptidecrotamine drug delivery scaffoldcrotamine sodium channel blockercrotamine proliferation selective uptakevenom derived cell penetrating peptide researchcrotamine nanoparticle deliverybuy crotamine research peptidecrotamine nuclear targeting peptidecrotamine vs TAT peptide comparison

Ready to take the next step?

Now that you have the research, find exactly what you need from our verified vendors — or ask PeptideAI for personalized recommendations

Looking for more? Buy peptides online from the #1 peptide research platform.